Image

Clinical Characteristics and Outcomes Among STEMI Patients With Cardiogenic Shock at Abu Dhabi City

Clinical Characteristics and Outcomes Among STEMI Patients With Cardiogenic Shock at Abu Dhabi City

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

A retrospective study on the clinical characteristics and treatment outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI) complicated with cardiogenic shock (CS) during admission or CS development during their hospital stay for two tertiary hospitals in Abu Dhabi, UAE, from 2020-2024.

Description

Cardiovascular disease (CVD) accounts for 40% of mortality in the UAE, which is higher than the global average. Long-term trends, incidence studies, and best practice guidance on Cardiogenic Shock (CS) with ST-elevation Myocardial infarction (STEMI) in the United Arab Emirates (UAE) and the Gulf Cooperation Council (GCC) are limited.

Through this retrospective study, investigators aim to identify treatment modalities and trends, hospitalization events, and patient demographics and comorbidities which lead to participant recovery or mortality in Sheikh Khalifa Medical City (SKMC) and Sheikh Shakhbout Medical City (SSMC) tertiary hospitals for patients admitted with STEMI and CS or developed CS after hospitalization with STEMI during January 2020-January 2024.[200-400 participants]. Data will be collected from eligible patients' electronic medical records (EMR).

Eligibility

Inclusion Criteria:

  • Age more than 18.
  • STEMI complicated by cardiogenic shock.
  • Were hospitalized or treated at SSMC or SKMC for STEMI complicated by cardiogenic shock.
  • Patient admitted between January 2019 to March 2024.

Exclusion Criteria:

  • Age less than 18.
  • Shock patient not related to Myocardial infarction.
  • NSTEMI-related cardiogenic shock.
  • Patients who were not treated at SSMC or SKMC for the STEMI complicated by cardiogenic shock.
  • Patient not admitted between January 2019 to March 2024.

Study details
    ST Elevation Myocardial Infarction
    Cardiogenic Shock

NCT06535503

Abu Dhabi Health Services Company

21 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.